论文部分内容阅读
目的:检测武汉地区乙型肝炎病毒的基因型与耐药突变基因,为临床治疗乙型肝炎患者提供实验室依据。方法:采用PCR-反向斑点杂交法对308例乙肝患者进行乙肝病毒基因型分析,同时检测拉米夫定耐药突变基因和阿德福韦酯耐药突变基因。结果:308例乙肝患者中检出B基因型173例,C基因型78例,B/C混合基因型6例,未检出51例。123例(39.94%)患者的HBV出现拉米夫定耐药,涉及3个位点4个突变型;34例(11.03%)出现阿德福韦酯耐药突变,涉及2个位点2个突变型。结论:武汉地区乙肝病毒存在较高的耐药基因突变率,对乙肝患者进行抗病毒治疗前和治疗过程中,应检测耐药基因是否出现突变。
Objective: To detect the genotypes and drug resistance mutations of hepatitis B virus in Wuhan area, and to provide a laboratory basis for the clinical treatment of patients with hepatitis B. Methods: Genotypes of 308 patients with hepatitis B were analyzed by PCR-reverse dot blot hybridization, and the resistance mutations of lamivudine and adefovir dipivoxil were also detected. Results: There were 173 cases of B genotype, 78 cases of C genotype and 6 cases of B / C mixed genotype in 308 cases of hepatitis B patients, 51 cases were not detected. HBV in 123 patients (39.94%) had lamivudine resistance, which involved 4 mutants in 3 loci; adefovir dipivoxil resistance mutation in 34 patients (11.03%), including 2 loci in 2 loci Mutant. Conclusion: There is a high rate of resistance gene mutation in hepatitis B virus in Wuhan area. Before and during the treatment of hepatitis B virus, the mutation of drug resistance gene should be detected.